FY2025 EPS Estimates for Codexis Cut by Cantor Fitzgerald

Codexis, Inc. (NASDAQ:CDXS) – Cantor Fitzgerald decreased their FY2025 earnings per share estimates for Codexis in a report released on Thursday, May 15th. Cantor Fitzgerald analyst K. Kluska now expects that the biotechnology company will post earnings of ($0.62) per share for the year, down from their previous estimate of ($0.60). The consensus estimate for Codexis’ current full-year earnings is ($0.77) per share.

Separately, StockNews.com upgraded shares of Codexis to a “sell” rating in a report on Friday, May 16th.

Codexis Stock Performance

NASDAQ:CDXS opened at $2.45 on Monday. The company has a market cap of $202.97 million, a P/E ratio of -2.82 and a beta of 2.56. Codexis has a twelve month low of $1.90 and a twelve month high of $6.08. The company’s 50-day moving average price is $2.43 and its 200-day moving average price is $3.72. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39.

Codexis (NASDAQ:CDXS) last announced its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.05). Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. The business had revenue of $7.54 million for the quarter, compared to analyst estimates of $10.38 million.

Institutional Investors Weigh In On Codexis

Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Codexis by 7.5% during the fourth quarter. Vanguard Group Inc. now owns 4,463,801 shares of the biotechnology company’s stock worth $21,292,000 after purchasing an additional 311,082 shares during the period. Telemark Asset Management LLC boosted its stake in Codexis by 11.3% during the fourth quarter. Telemark Asset Management LLC now owns 3,000,000 shares of the biotechnology company’s stock worth $14,310,000 after buying an additional 303,589 shares during the period. Ameriprise Financial Inc. grew its stake in shares of Codexis by 0.5% in the fourth quarter. Ameriprise Financial Inc. now owns 2,399,650 shares of the biotechnology company’s stock valued at $11,446,000 after buying an additional 12,625 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Codexis by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 1,855,514 shares of the biotechnology company’s stock valued at $8,853,000 after purchasing an additional 211,475 shares in the last quarter. Finally, Nuveen Asset Management LLC boosted its stake in shares of Codexis by 18.6% in the 4th quarter. Nuveen Asset Management LLC now owns 1,812,345 shares of the biotechnology company’s stock valued at $8,645,000 after buying an additional 283,760 shares during the period. Hedge funds and other institutional investors own 78.54% of the company’s stock.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.